AI-Enabled Drug Development: Best Practices for Mitigating Risks and Ensuring Good Governance

Winston’s Health Care & Life Sciences team hosted an insightful webinar featuring Intellectual Property, Competition, and AI partner Kathi Vidal, who recently returned to Winston after serving as Under Secretary of Commerce for Intellectual Property and Director of the USPTO since 2022.

Our attorneys discussed how generative AI is revolutionizing drug discovery, preclinical testing, and clinical trials. They outlined key associated risks in the areas of intellectual property, product liability, and data privacy while sharing actionable strategies to mitigate these risks and ensure robust AI governance.

Access the slides here.